Badanie terapii genowej z użyciem atidarsagene autotemcel u pacjentów z leukodystrofią metachromatyczną (MLD)

Metachromatic Leukodystrophy (MLD) is a rare genetic disorder that affects the nervous system, leading to a gradual loss of physical and mental abilities. This study focuses on a treatment called Libmeldy, which is a type of gene therapy. The treatment involves using a special preparation of cells called atidarsagene autotemcel. These cells are modified to carry a healthy version of a gene that is missing or not working properly in people with MLD. The goal of the study is to see how effective this treatment is in improving the condition of patients with early onset MLD.

The study uses a method where the modified cells are given to the patient through a direct intravenous injection. This means the cells are introduced directly into the bloodstream. The study is designed to observe the effects of the treatment over a period of time, with regular check-ups to monitor the patient's progress. The main focus is on how well the patients can move and perform physical activities after receiving the treatment. Other aspects, such as brain function and nerve health, are also evaluated to understand the overall impact of the therapy.

Participants in the study are closely monitored for any side effects or changes in their health. The study aims to provide valuable information on the safety and benefits of using Libmeldy for treating MLD, potentially offering a new option for managing this challenging condition. The study is expected to continue until 2025, allowing researchers to gather comprehensive data on the long-term effects of the treatment.